Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from BioMarin

2 'Strong Buy'-Rated Stocks That Could Rally 39% to 48% in 2025

Both of these growth stocks are positioned for long-term success.

Barchart

Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug

Ascendis Pharma stock rocketed Monday on promising test results for a growth treatment that could rival BioMarin's approved drug, Voxzogo.

Investors Business Daily

Innovating in Biotech This Stock Targets Unmet Medical Needs for Big Profit

Most biotechnology companies have a broad mandate to perform research and development that addresses the largest market possible. It makes logical sense, the largest market should be the most profitable. But Biomarin stands this model on its head, providing drug treatments for highly specialized, mostly small markets that are underserved,…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

BioMarin Surges As Activist Investor Elliott Reportedly Builds $1 Billion Stake

Activist investor Elliott has reportedly built a $1 billion stake in BioMarin Pharmaceutical, Reuters reported Tuesday as BMRN stock rocketed.

Investors Business Daily

Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?

The big names behind biotech stocks no longer want to merely treat diseases, they want to cure them. But it's going to be costly.

Investors Business Daily

Gene therapy for severe hemophilia is approved by FDA

U.S. health regulators have approved a gene therapy for the most common form of hemophilia

The Independent UK

Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin Pharmaceuticals

PTC stock surged Wednesday after the company unveiled promising results for its rare disease treatment, a rival to BioMarin's Kuvan.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Dow Jones Futures Rise To Start 2023; Tesla Falls On This Delivery Red Flag

Dow Jones futures kick off the 2023 stock market after a "stay away" year. Q4 Tesla deliveries hit a record, but missed lowered views again.

Investors Business Daily

The FDA Just Approved Its Most Expensive Drug Ever — Sending UniQure Stock On A Warpath

The FDA just approved its most expensive drug ever — a hemophilia gene therapy from CSL and UniQure — and QURE stock popped Wednesday.

Investors Business Daily

Neurocrine Leads 5 Stocks To Watch In Sickly Market

Neurocrine Biosciences leads five medical stocks near key support levels as the health care sector shows resilience in a sickly market.

Investors Business Daily

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ:BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the treatment of severe hemophilia A (congenital Factor VIII deficiency) in adult patients. BioMarin shares traded as high as 2.28 percent, in a range of $91.39 to $93.68…

Benzinga

Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them

A handful of pharmaceutical stocks — including Pfizer and Amgen — are either eyeing buy points or have broken out after diving in June.

Investors Business Daily

BioMarin Achieves Record Q1 Sales Driven By Recently Approved Achondroplasia Therapy

BioMarin Pharmaceutical Inc's (NASDAQ:BMRN) Q1 sales reached $519 million, up 7% Y/Y, beating the consensus of $507.52 million. BioMarin said that the increase was achieved "despite continued erosion of the U.S. Kuvan market." Kuvan is indicated for phenylketonuria. Kuvan still brought in $59.3 million but down from $70.8 million a year ago.…

Benzinga

BioMarin Clocks Flat Q4 Sales Despite Erosion oF US Kuvan Market

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) reported a 1% Y/Y decrease in Q4 revenue to $449.8 million, beating the consensus estimate of $442.39 million. The decline was attributable to lower sales from Kuvan and Naglazyme, cushioned by higher revenues from Aldurazyme, Vimizim, and Palynziq. Kuvan sales decreased 23% to $ 68.5 million, primarily due…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

BioMarin Stock Dives As FDA Questions The Safety Of Its Gene Therapy

BioMarin stock tumbled Friday on a Food and Drug Administration setback for its experimental gene therapy in a rare disease.

Benzinga

FDA Asks For More Data To Resolve BioMarin's Gene Therapy Clinical Hold

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) said that the

Benzinga

BioMarin Sells Priority Review Voucher For $110M

BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has agreed to sell the Rare Pediatric Disease Priority Review Voucher (PRV)

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.